INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2016

Hepatic NAD(+) decline occurred with ageing in humans and mice, and oral nicotinamide riboside corrected NAFLD phenotypes in mice.

Investigators compared hepatic NAD(+) and NAD(+) biosynthesis enzymes in middle-aged and aged mice and patients, and tested the effects of high-fat diet and nicotinamide riboside in DN-NAMPT transgenic mice. Hepatic NAD(+) levels decreased in aged mice and humans, with compromised NAMPT-controlled NAD(+) salvage. Middle-aged DN-NAMPT mice fed normal chow displayed systemic NAD(+) reduction and moderate NAFLD phenotypes, which deteriorated under a high-fat diet. Oral administration of nicotinamide riboside completely corrected these NAFLD phenotypes.

Study type
Comparative tissue analysis and animal intervention study
Who was studied
Middle-aged and aged mice and human patients
What was measured
Hepatic NAD(+) levels, NAMPT protein levels, steatosis, inflammation, and fibrosis

THE PAPER

Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.

Zhou CC, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, Li ZY, Guan YF, Wang P, Miao CY. Br J Pharmacol, 2016.

PubMed 27174364 ↗DOI 10.1111/bph.13513 ↗

Nutrients & adequacyHealthy aging & longevityOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.